Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Annamycin,Cytarabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Polish National Center for Research and Development
Deal Size : $6.7 million
Deal Type : Funding
WPD Pharmaceuticals to Receive $6.7 Million Grant for Development of Annamycin Drug Candidate
Details : Annamycin is a "next generation" anthracycline, that has been shown to be less cardiotoxic compared to other anthracycline, such as doxorubicin, and to avoid multidrug resistance, so the use of Annamycin may not face the same dose limitations imposed on ...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 11, 2021
Lead Product(s) : Annamycin,Cytarabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Polish National Center for Research and Development
Deal Size : $6.7 million
Deal Type : Funding
Lead Product(s) : Berubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Berubicin is a second-generation anthracycline candidate for the treatment of a number of Central Nervous System Cancers, including Glioblastoma Multiforme (GBM) and Malignant Gliomas.
Brand Name : RTA 744
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 27, 2021
Lead Product(s) : Berubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Annamycin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Moleculin Biotech
Deal Size : Undisclosed
Deal Type : Funding
Details : WPD entered into the amendment of its February 2019 sublicense from Moleculin of certain IP rights, including the rights to Annamycin, WP1066 and WP1122 portfolios to research, develop, manufacture, use, import, offer and sell products derived from these...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 30, 2021
Lead Product(s) : Annamycin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Moleculin Biotech
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Annamycin
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Moleculin Biotech
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Annamycin is a "next generation" anthracycline that has recently been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin. Annamycin has also demonstrated a lack of cardiotoxicity in recently conducted human clinic...
Brand Name : L-ANN
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 30, 2021
Lead Product(s) : Annamycin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Moleculin Biotech
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : WP1122
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Dermin
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaborative agreement, WPD is not required to pay Dermin or grant a royalty for the rights transferred, but is required to provide Dermin with all its research data, if any, which Dermin may use for the further development of WP1122 as an ant...
Brand Name : WP1122
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 17, 2020
Lead Product(s) : WP1122
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Dermin
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : WP1122
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : CNS Pharmaceuticals
Deal Size : $1.0 million
Deal Type : Agreement
CNS Provides Update on Development Agreement for WP1122
Details : Under the terms of the development agreement with WPD Pharmaceuticals, CNS agreed to fund a portion of the development costs of WP1122 and other drug candidates for antiviral indications in exchange for certain economic rights.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $0.2 million
May 27, 2020
Lead Product(s) : WP1122
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : CNS Pharmaceuticals
Deal Size : $1.0 million
Deal Type : Agreement
Lead Product(s) : Annamycin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The US Phase 1 trial shows the safety of Annamycin in a phase I trial setting when delivered to patients at or below the lifetime maximum anthracycline dose established by the FDA.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 23, 2020
Lead Product(s) : Annamycin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : WP1122
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Independent research on in WPD Pharmaceutical's WP1122 drug compound found 2-deoxy-D-glucose (“2-DG”) to reduce replication of SARS-CoV-2.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 09, 2020
Lead Product(s) : WP1122
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : WP1122
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : CNS Pharmaceuticals
Deal Size : $1.0 million
Deal Type : Agreement
CNS Pharmaceuticals Signs Agreement with WPD Pharmaceuticals
Details : CNS Pharmaceuticals has entered into an agreement with WPD Pharmaceuticals Inc for the development of several preclinical drug candidates including WP1122.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $0.2 million
March 23, 2020
Lead Product(s) : WP1122
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : CNS Pharmaceuticals
Deal Size : $1.0 million
Deal Type : Agreement
Details : WP1066 drug candidate received FDA approval for Investigational New Drug status to be used in a Phase 1 clinical trial for recurrent or refractory malignant brain tumors in children.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 20, 2020
LOOKING FOR A SUPPLIER?